thalidomide has been researched along with Central Nervous System Tuberculosis in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, an anti-inflammatory and immunomodulatory agent, has a potential role in cases with central nervous system tuberculosis (CNS-TB) with paradoxical reactions." | 9.12 | Efficacy and Safety of Thalidomide in Patients with Complicated Central Nervous System Tuberculosis: A Systematic Review and Meta-Analysis. ( Dawman, L; Panda, P; Panda, PK; Sharawat, IK; Sihag, RK, 2021) |
| "Thalidomide has been trialled in CNS TB due to its immunomodulatory and immune reconstitution effects through the inhibition of tumour necrosis factor alpha." | 5.48 | Clinical perspectives into the use of thalidomide for central nervous system tuberculosis. ( Adams, A; Bharambe, V; Gnanapavan, S; Jayakumar, A; Keddie, S; Sanchez, V; Shah, A, 2018) |
| "Thalidomide is a drug with pleiotropic effects: it appears to downregulate production of TNF-alpha and other proinflammatory cytokines." | 2.46 | Management of central nervous system tuberculosis in children: light and shade. ( Buonsenso, D; Serranti, D; Valentini, P, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Toorn, R | 1 |
| Solomons, RS | 1 |
| Seddon, JA | 1 |
| Schoeman, JF | 1 |
| Panda, PK | 1 |
| Panda, P | 1 |
| Dawman, L | 1 |
| Sihag, RK | 1 |
| Sharawat, IK | 1 |
| Keddie, S | 1 |
| Bharambe, V | 1 |
| Jayakumar, A | 1 |
| Shah, A | 1 |
| Sanchez, V | 1 |
| Adams, A | 1 |
| Gnanapavan, S | 1 |
| Buonsenso, D | 1 |
| Serranti, D | 1 |
| Valentini, P | 1 |
2 reviews available for thalidomide and Central Nervous System Tuberculosis
| Article | Year |
|---|---|
Efficacy and Safety of Thalidomide in Patients with Complicated Central Nervous System Tuberculosis: A Systematic Review and Meta-Analysis.
Topics: Immunosuppressive Agents; Thalidomide; Tuberculosis, Central Nervous System | 2021 |
Management of central nervous system tuberculosis in children: light and shade.
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Humans; Magnetic Resonance Imaging; Randomized Contr | 2010 |
2 other studies available for thalidomide and Central Nervous System Tuberculosis
| Article | Year |
|---|---|
Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort.
Topics: Adult; Antitubercular Agents; Child; Humans; Retrospective Studies; Thalidomide; Tuberculosis, Centr | 2021 |
Clinical perspectives into the use of thalidomide for central nervous system tuberculosis.
Topics: Adult; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Thalidomide; Treatment Outcome; | 2018 |